RAD001-mediated STAT3 upregulation and megakaryocytic differentiation

Summary

RAD001 is currently used as an immunosuppressant and anticancer drug. Megakaryocyte (MK) differentiation includes development from pluripotent stem cells to proliferation and differentiation toward MK formation and platelet maturation. Our preliminary assay showed that RAD001 might stimulate MK differentiation; however, the exact regulatory mechanisms needed to be elucidated. By the ex vivo assay, RAD001 induced MK differentiation in human haematopoietic stem cells, with both the stimulation of CFU-GM colony formation and CD61 surface marker expression. Then, BALB/c mice were orally administrated with or without agrylin and/or RAD001 for 15 days. The platelet count and bone marrow CFU-MK colony formation were eliminated by agrylin, but unchanged in RAD001 and RAD001 plus agrylin mice. An ex vivo assay of bone marrow-derived stem cells demonstrated that RAD001 increased the number of CFU-MK colonies. The MK count in bone section indicated the decreased effect by agrylin and then recovered by RAD001. The level of plasma thrombopoietin was also enhanced in RAD001-treated mice. The effect of RAD001 on human leukaemic K562 and HEL cells showed the growth inhibition and MK differentiation activities; including morphological observation, CD41 and CD61 expression, and platelet factor 4 secretion. In RAD001-treated HEL cells, p-STAT3 expression, STAT3 translocation, and STAT3-DNA binding activity were up-regulated. Furthermore, STAT3 siRNA decreased the p-STAT3 and CD61 expression, as well as the CD61 fluorescence intensity, indicating that STAT3 may be critical in RAD001-mediated MK differentiation. Conclusion, the present study demonstrated that RAD001 might have the capacity to induce MK differentiation through the up-regulation of STAT3 signalling.

Keywords

RAD001 - megakaryocytic differentiation - agrylin - leukaemia - STAT3

• References

• 1 Cataneo-Davila A, Zuniga-Varga J, Correa-Rotter R. et al. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Transplant Proc 2009; 41: 4138-4146.
• 2 Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010; 25: 91-101.
• 3 Lott DG, Dan O, Lu L. et al. Long-term laryngeal allograft survival using low-dose everolimus. Otolaryngol Head Neck Surg 2010; 142: 72-78.
• 4 Beuvink I, Boulay A, Fumagalli S. et al. The mTOR inhibitor RAD001 sensitizes tumour cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759.
• 5 Alonso MM, Jiang H, Yokoyama T. et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 2008; 16: 487-493.
• 6 Altmeyer A, Josset E, Denis JM. et al. The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. Int J Oncol 2012 Epub ahead of print.
• 7 Yang J, Ikezoe T, Nishioka C. et al. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp Hematol 2010; 38: 666-676.
• 8 Nishioka C, Ikezoe T, Yang J. et al. Inhibition of mammalian target of rapamycin signalling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukaemia cells. Int J Cancer 2009; 125: 1710-1720.
• 9 Patel SR, Hartwig JH, Italiano Jr JE. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005; 115: 3348-3354.
• 10 Sevinsky JR, Whalen AM, Ahn NG. Extracellular signal-regulated kinase induces the megakaryocyte GPIIb/CD41 gene through MafB/Kreisler. Mol Cell Biol 2004; 24: 4534-4545.
• 11 Pan R, Wang J, Nardi MA. et al. The inhibition effect of anti-GPIIIa49-66 antibody on megakaryocyte differentiation. Thromb Haemost 2011; 106: 484-490.
• 12 Rubinstein JD, Elagib KE, Goldfarb AN. Cyclic AMP signalling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin-dependent kinase inhibitor 1A (CDKN1A) transcriptional axis. J Biol Chem 2012; 287: 19207-19215.
• 13 Louwette S, Labarque V, Wittevrongel C. et al. Regulator of G-protein signalling 18 controls megakaryopoiesis and the cilia-mediated vertebrate mechanosensory system. FASEB J 2012; 26: 2125-2136.
• 14 Cornejo MG, Mabialah V, Sykes SM. et al. Crosstalk between NOTCH and Akt signalling during murine megakaryocyte lineage specification. Blood 2011; 118: 1264-1273.
• 15 Peng HY, Liao HF. Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signalling pathway. Ann Hematol 2011; 90: 1017-1029.
• 16 Liu ZJ, Italiano Jr. J, Ferrer-Marin F. et al. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signalling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood 2011; 117: 4106-4117.
• 17 Jeanpierre S, Nicolini FE, Kaniewski B. et al. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signalling. Blood 2008; 112: 3154-3163.
• 18 Fuhler GM, Tyl MR, Olthof SG. et al. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells. Eur J Haematol 2009; 83: 235-245.
• 19 Yilmaz VT, Koçak H, Avci AB. et al. Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol 2011; 43: 581-584.
• 20 Houghton PJ. Everolimus. Clin Cancer Res 2010; 16: 1368-1372.
• 21 Zuccato C, Bianchi N, Borgatti M. et al. Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells. Acta Haematol 2007; 117: 168-176.
• 22 Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
• 23 Guerriero R, Parolini I, Testa U. et al. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci 2006; 119: 744-752.
• 24 Ho AL, Deraje Vasudeva S, Lae M. et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012; 72: 4515-4525.
• 25 Yu M, Cantor AB. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods Mol Biol 2012; 788: 291-303.
• 26 Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005; 18: 243-249.
• 27 He D, Chen T, Yang M. et al. Small Rab GTPase Rab7b promotes megakaryocytic differentiation by enhancing IL-6 production and STAT3-GATA-1 association. J Mol Med 2011; 89: 137-150.
• 28 Nakatake M, Kakiuchi Y, Sasaki N. et al. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007; 6: 1496-1501.
• 29 Bussel JB, Cheng G, Saleh M. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
• 30 Stasi R, Evangelista ML, Stipa E. et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.